



## Pharmacy Services

### San Francisco Health Plan Pharmacy & Therapeutics Committee

Wednesday, January 19, 2022

Remote Vote Held Via Email

<b>Meeting called by:</b>	James Glauber, MD (Via Email Vote)	<b>Minutes:</b> Luke Nelson (SFHP Pharmacy Analyst)
<b>Meeting Objective:</b>	Vote on proposed formulary and prior authorization (PA) criteria changes	<b>Type of meeting:</b> Quarterly- Interim Vote via Email
<b>Member Votes Cast:</b>	<b>Voting Members:</b> James Glauber, MD (SFHP Health Plan Physician Advisor) Lisa Ghotbi, Pharm. D (SFHP Director of Pharmacy) Nicholas Jew, MD Ronald Ruggiero, Pharm. D Robert (Brad) Williams, MD Jamie Ruiz, MD Linda Truong, Pharm. D Maria Lopez, Pharm. D	<b>Others in Attendance:</b> No attendance this meeting, remote voting only.
<b>Members Absent:</b>	Steven Wozniak, MD Joseph Pace, MD	
<b>Meeting Materials:</b>	Summary of all approved changes is posted under “Materials” section at <a href="https://www.sfhp.org/about-us/committees/pharmacy-and-therapeutics-committee/">https://www.sfhp.org/about-us/committees/pharmacy-and-therapeutics-committee/</a> SFHP formulary and prior authorization criteria are located at <a href="https://www.sfhp.org/providers/pharmacy-services/sfhp-formulary/">https://www.sfhp.org/providers/pharmacy-services/sfhp-formulary/</a>	

	Topic	Brought By	Discussion	Action
1.	Review and Approval of October 20, 2021 P&T minutes (pp.4 - 10 of January 2022 P&T Packet)	Kaitlin Hawkins, Pharm. D	The committee approved the minutes as presented.	<b>VOTE:</b> <b><u>Review and Approval of October 20, 2021 P&amp;T Minutes</u></b> Approved minutes as presented.  <i>Vote: Unanimous approval (8/8)</i>
2.	<b><u>Cardiology</u></b> Hypertension Class Review (pp.11 - 37)	Kaitlin Hawkins, Pharm. D	The plan presented a class review and recommendations for hypertension medications. Major recommendations included the following: <b>Last reviewed:</b> January 2020 <b>Formulary Update:</b> (Healthy Workers HMO and Healthy San Francisco): <ul style="list-style-type: none"> <li>Remove fosinopril, quinapril, and ramipril from formulary due to lack of utilization and multiple alternative ACE inhibitors available</li> <li>Remove nadolol, pindolol, and propranolol oral solution from</li> </ul>	<b>VOTE:</b> <b><u>Cardiology:</u></b> Approved recommendations as presented.  <b><u>Hypertension Class Review</u></b> <i>Vote: Unanimous approval (8/8)</i>

	Topic	Brought By	Discussion	Action
			<p>formulary due to lack of utilization and multiple alternative beta blockers available</p> <ul style="list-style-type: none"> <li>Remove Diuril® (chlorothiazide) oral suspension from formulary due to lack of use or pediatric members</li> <li>Remove phenoxybenzamine (Dibenzyl®) 10mg capsule from formulary due to lack of utilization and limited place in therapy</li> </ul> <p><b>PA Criteria Update:</b></p> <ul style="list-style-type: none"> <li>Retire Phenoxybenzamine (Dibenzyl®) criteria due to formulary removal and Blood Pressure Monitors criteria due to termination of SFHP Medi-Cal pharmacy benefit</li> <li>Update Controlled-Release Carvedilol (Coreg CR®) criteria to include hypertension as a labeled indication</li> </ul> <p><b>DUR Update:</b></p> <ul style="list-style-type: none"> <li>Antihypertensive adherence analysis presented separately, recommending member/provider education</li> </ul> <p><b>Committee Discussion:</b> <i>The committee had no comments or questions.</i></p>	
3.	<p><b>Cardiology</b> Antihypertensives Drug Utilization Review (pp.38 - 40)</p>	Jessica Shost, Pharm. D	<p><i>The plan presented a DUR monitoring review of Antihypertensives.</i></p> <p><b>Goal:</b></p> <ul style="list-style-type: none"> <li>Assess adherence for Medi-Cal members on medications to treat hypertension.</li> </ul> <p><b>Recommendations:</b></p> <ul style="list-style-type: none"> <li>Provide educational materials to members, specifically targeting members in demographic groups with lower adherence rates</li> <li>Provide educational materials to providers to assist in addressing barriers to medication adherence</li> </ul> <p><b>Committee Discussion:</b> <i>Dr Glauber commented that it may be prudent to update this analysis when sufficient time with the new Medi-Cal Rx benefit passes. This may require more analysis and discussion before deciding on an intervention.</i></p>	Non-voting item
4.	<p><b>Dermatology</b> Actinic Keratosis Class Review (pp.41 - 47)</p>	Kaitlin Hawkins, Pharm. D	<p><i>The plan presented a class review and recommendations for dermatology medications.</i></p> <p><i>Major recommendations included the following:</i></p> <p><b>Last reviewed:</b> January 2020</p> <p><b>Formulary Update:</b> (Healthy Workers HMO and Healthy San Francisco):</p> <ul style="list-style-type: none"> <li>No changes are recommended</li> </ul> <p><b>PA Criteria Update:</b></p> <ul style="list-style-type: none"> <li>None</li> </ul> <p><b>DUR Update:</b></p> <ul style="list-style-type: none"> <li>None</li> </ul> <p><b>Committee Discussion:</b> <i>The committee had no comments or questions.</i></p>	<p><b>VOTE:</b> <b>Dermatology:</b> Approved recommendations as presented.</p> <p><b>Actinic Keratosis Class Review</b> <i>Vote: Unanimous approval (8/8)</i></p>
5.	<p><b>Dermatology</b> Opzelura® (ruxolitinib) Monograph (pp.48 - 57)</p>	Kaitlin Hawkins, Pharm. D	<p><i>Major recommendations included the following:</i></p> <p><b>Last reviewed:</b> n/a</p> <p><b>Formulary Update:</b> (Healthy Workers HMO and Healthy San Francisco):</p>	<p><b>VOTE:</b> <b>Dermatology:</b> Approved recommendations as presented.</p>

	Topic	Brought By	Discussion	Action
			<ul style="list-style-type: none"> <li>Maintain non-formulary at this time due to limited place in therapy and cost-effective alternatives on formulary</li> </ul> <p><b>PA Criteria Update:</b></p> <ul style="list-style-type: none"> <li>Update Atopic Dermatitis criteria to list Opzelura™ as non-preferred, on par with Eucrisa®</li> </ul> <p><b>DUR Update:</b></p> <ul style="list-style-type: none"> <li>None</li> </ul> <p><b>Committee Discussion:</b>  <i>The committee had no comments or questions.</i></p>	<p><b><u>Opzelura® (ruxolitinib) Monograph</u></b>  <i>Vote: Unanimous approval (8/8)</i></p>
6.	<p><b><u>Nephrology</u></b>  Kerendia® (finerenone) Monograph  (pp.58 - 65)</p>	Kaitlin Hawkins, Pharm. D	<p><i>The plan presented a monograph and recommendations for nephrology medications.</i>  <i>Major recommendations included the following:</i></p> <p><b>Last reviewed:</b> n/a</p> <p><b>Formulary Update:</b>  (Healthy Workers HMO)</p> <ul style="list-style-type: none"> <li>Add to formulary tier 3 with prior authorization required to ensure appropriate use</li> </ul> <p><b>PA Criteria Update:</b></p> <ul style="list-style-type: none"> <li>Implement new drug-specific criteria requiring documentation of diagnosis, baseline labs, and background ACE inhibitor or ARB</li> </ul> <p><b>DUR Update:</b></p> <ul style="list-style-type: none"> <li>None</li> </ul> <p><b>Committee Discussion:</b>  <i>Dr Ruggiero commented that a patient must have serum K+ less than or equal to 4.8 mmol/L. Note importance of periodic serum K+ levels as needed.</i></p>	<p><b>VOTE:</b>  <b><u>Nephrology:</u></b>  Approved recommendations as presented.</p> <p><b><u>Kerendia® (finerenone) Monograph</u></b>  <i>Vote: Unanimous approval (8/8)</i></p>

7.	Review and Approval of Prior Authorization Criteria Interim Changes (pp.66 - 67)	Kaitlin Hawkins, Pharm. D	<i>The plan presented Prior Authorization Criteria interim changes (New Criteria, Revised Existing Criteria &amp; a table of criteria that were evaluated per the Annual review process where no clinical changes were made) for review and approval</i>  <b><u>Committee Discussion:</u></b> <i>The committee had no comments or questions.</i>	<b><u>VOTE:</u></b> <b><u>Review and Approval of Prior Authorization Criteria Interim Changes</u></b> Approved recommendations as presented.  <i><u>Vote: Unanimous approval (8/8)</u></i>
8.	Review and Approval of Interim Formulary Changes and Formulary Placement for New Drugs to Market (pp.68 - 70)	Kaitlin Hawkins, Pharm. D	<i>The plan presented interim formulary changes and formulary status for new drugs to market.</i>  <b><u>Committee Discussion:</u></b> <i>The committee had no comments or questions.</i>	<b><u>VOTE:</u></b> <b><u>Review and Approval of Interim Formulary Changes and Formulary Placement for New Drugs to Market</u></b> Approve recommendations as presented.  <i><u>Vote: Unanimous approval (8/8)</u></i>
9.	<b><u>Appendix</u></b> Magellan Pipeline Report (pp 71 -117)	Kaitlin Hawkins, Pharm. D	<i>The plan provided information published by Magellan Rx regarding new developments in the pharmacy market.</i>	<i>Non-voting item</i>
10.	Vote Collection	Luke Nelson	The committee email vote was closed at 5pm.  2021-2022 P&T Committee Meeting dates are: <ul style="list-style-type: none"> <li>• Wednesday, April 20, 2022</li> <li>• Wednesday, July 20, 2022</li> <li>• Wednesday, October 19, 2022</li> <li>• Wednesday, January 18, 2022</li> </ul>	

Respectfully submitted by:

*Fiona Donald, MD*

-----  
Fiona Donald, MD  
Chief Medical Officer

4/26/2022

-----  
Date